Clinical studies have shown that a large percentage of adult women worldwide suffer from sexual complaints. Low desire is consistently reported as the most common sex-related complaint. As a result, many women are dissatisfied with their sex lives, which often affects their social and emotional wellbeing.
This has been classified as a clinical condition, referred to as Female Sexual Interest/Arousal Disorder (FSIAD) in the latest version of the Diagnostic and Statistical Manual of Mental Disorders, DSM-5. FSIAD is defined as a persistent lack or absence of sexual interest or arousal. Women suffering from this condition experience marked distress. The diagnosis requires that the complaints cannot be accounted for by a nonsexual mental disorder or as a consequence of severe relationship distress or other significant stressors and is not attributable to the effects of a substance/medication or another medical condition.
Currently, there are very few approved drugs for this condition. Various causes have been identified as being responsible for female sexual complaints. Emotional Brain has developed an innovative, personalized approach centered around two advanced medications that are designed to respond to the individual causes of FSIAD in each patient: Lybrido and Lybridos.
Emotional Brain’s research program has revealed that, although women with the same diagnosis of Female Sexual Interest/Arousal Disorder (FSIAD) may share similar symptoms, these symptoms may be caused by different factors.
Lybrido has been developed for patients with FSIAD, who are relatively insensitive to sexual cues. It increases central sexual motivation and physiological sexual responses, such as swelling of vaginal erectile tissue and lubrication.
Lybridos* has been developed for women with FSIAD whose sexual response is overly inhibited, for instance due to negative associations with sex. It enhances sexual motivation, as does Lybrido, but also dampens inhibitory mechanisms in the prefrontal cortex of the brain.
Both drugs can be taken ‘on demand’ and help to increase central sexual motivation about 3 to 6 hours after intake.
Moreover, we have developed an innovative classification system, based on genetic markers, that determines whether someone is likely to respond to Lybrido or Lybridos. This ensures that women suffering from FSIAD are prescribed the drug that specifically targets the mechanisms that cause their complaints.